Semaglutide or empagliflozin added to insulin injections in T1D
What this study tests
A completed randomized phase 2 study in Egypt compared insulin injections alone with insulin plus either semaglutide or empagliflozin in adults with T1D and BMI at least 27. The registry reports 114 actual participants but no results.
Editorial review: . 16 September review-note archive (earlier notes may not cover later changes).
Registry checked: 2026-09-17. Registry’s own update: 2026-09-02.
Most recent recorded citation date: 2026-09-02. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. Review coverage and open work · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults aged 18–65 with T1D for more than one year, BMI at least 27 kg/m², HbA1c 7.5–10%, and inadequate control despite at least one year of multiple daily insulin injections. Pump users were excluded. Further exclusions include recent emergency-treated hypoglycemia or DKA, gastroparesis, pancreatitis and pregnancy. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results are posted in ClinicalTrials.gov as of 17 September 2026. Registered endpoints and procedures are study plans, not evidence of benefit or safety.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: Other regions. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the 16 September review-note archive and current review coverage. Later changes and new records may not appear in the earlier notes. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Change in HbA1c from baseline after three months of treatment.
The full picture
This open-label, randomized, parallel-group study has three separate arms: insulin injections alone, insulin plus semaglutide, and insulin plus empagliflozin. It does not test semaglutide and empagliflozin together, and it excludes insulin-pump treatment. The registered site is in Tanta, Egypt.1
The registry reports actual enrollment of 114, but each arm description still anticipates 35 participants, totaling 105. The available record does not explain that discrepancy or provide actual arm-specific or analyzed denominators. Three months is the primary HbA1c assessment interval, not a reported treatment effect.1
The registry lists actual study start on 20 January 2025 and actual primary and study completion on 20 January 2026. The latest update was posted on 2 September 2026. Completion does not establish benefit or safety: no results are posted in this record.1
These are selected eligibility highlights. The registry excludes hypoglycemia requiring hospitalization or emergency care within three months and DKA requiring such care within 12 months, among other conditions. It describes research use of adjunct drugs, not an authorization or recommendation for T1D treatment.1
References
-
ClinicalTrials.gov. NCT06762314. Last update posted 2026-09-02; checked 17 September 2026. https://clinicaltrials.gov/study/NCT06762314 ↩ ↩2 ↩3 ↩4
Sources
- [1]Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes · Trial registry · 2026-09-02 — Original registry protocol, eligibility, outcomes and status checked 17 September 2026. Citation date is the last posted registry update, not a results publication.